Novo Nordisk has not disclosed its pricing plans for Saxenda yet, although there are rumours it is considering a price of $9,000 per year, which would be a significant premium to Victoza.

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

They took metformin and 1.8 milligrams of liraglutide for at least four weeks and experienced an average weight loss of about 20 pounds. Finally, a 2021 study funded by Novo Nordisk (the ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...